Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Novo Nordisk makes medicines for diabetes, obesity, and other serious chronic diseases.
Novo Nordisk is a Danish drugmaker best known for one thing: it makes the medicines that help people manage diabetes and lose weight. Its flagship products are injectable drugs like Ozempic for type 2 diabetes and Wegovy for obesity, both built on the same active ingredient, semaglutide. Patients use them to control blood sugar and to shed pounds, and lately the weight-loss use has turned these drugs into a global phenomenon.
The business makes money by selling these medicines at a premium, mostly in the United States and Europe, where it charges far more than in most other markets. Doctors prescribe them, insurers and patients pay, and Novo keeps a fat margin because making a reliable copy of this kind of drug is genuinely hard. The company also sells older insulin products and treatments for rare blood disorders, but the diabetes and obesity drugs are the engine. What makes Novo strong is a mix of science and manufacturing muscle. It spent decades learning how to make and package injectable drugs at enormous scale, and that know-how became a moat when demand for Wegovy and Ozempic exploded faster than anyone expected. The catch is that rivals are catching up. Eli Lilly has its own powerful weight-loss drugs, and the two are now fighting for the same patients. Novo has also faced supply shortages, and a big worry is whether insurers will keep paying high prices as competition grows.
Novo's growth has been startling. Revenue climbed sharply in recent years as the weight-loss drugs took off, making it one of the most valuable companies in Europe. It spends heavily on factories to keep up with demand and on research to stay ahead. The stock has swung wildly as investors argue over how long this boom lasts, and a big dose of its future now hangs on whether it can defend its lead against Eli Lilly and keep insurers and governments from squeezing what they pay.
Saved answer 路 last researched 6 Nov 2026